Hepatitis C

Awareness programme on problems related to Thalassemia and Hepatitis C

Watch Video Recording of the program here

Children's Liver Foundation & THINK Foundation

under the aegis of

International Coalition of Hepatology Education Providers 

invite you to an

Awareness programme on problems related to

Thalassemia and Hepatitis C

on Monday  July 28, 2014, Hall of Harmony, Nehru Centre,

Dr. Annie Besant Road, Worli, Mumbai 400025. Time:  3.00 pm to 7.00 pm

WORLD HEPATITIS DAY

  • Dr. Rashid Merchant - Thalassemia and long term issues
  • Dr. Mamta Manglani - Reducing iron overload in patients of Thalassemia  
  •  Dr. Aabha Nagral- Thalassemia and Hepatitis C - Prevention and Management
  • Mr. Vinay Shetty- How can we help the Thalassemic child lead a normal life?
  • Imran  -My journey with Thalassemia and Hepatitis C
Post by Children's Liver Foundation.
Read more

Thalassemia Major with Hepatitis C -- A double whammy...

Source Event :Case discussions in Pediatric Liver Diseases organised by Children's Liver Foundation and Indian Academy of pediatric, Mumbai on 14th and 15th December 2013.
See video

Presented by Dr Tapobrata De
Moderated by Dr Prabha Sawant
Panelists Dr Winita Hardikar
Dr Mukesh Agarwal
Dr Mamta Manglani

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings

Maternal neighbourhood-level social determinants of health and their association with paediatric hepatitis C screening among children exposed to hepatitis C in pregnancy

The Efficacy and Safety of Sofosbuvir and Daclatasvir Treatment in Children and Adolescents With Thalassemia and Hepatitis C Virus Infectio

Health-related quality of life in patients aged 6-18 years with chronic hepatitis C treated with sofosbuvir/velpatasvir

Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission

Ledipasvir-sofosbuvir in Adolescents with Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy

Outcome of Treatment in Children With Chronic Viral Hepatitis C: A Single Centre Study

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project

One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis-A Case Series Report

Chronic Hepatitis Is Common and Often Untreated Among Children With Hepatitis B Infection in the United States and Canada

Hepatitis C Virus in Neonates and Infants

Seroprevalence of Hepatitis C in Children without Identifiable Risk-Factors: A Systematic Review and Meta-Analysis

Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children

Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a

Hepatitis in Children With Tuberculosis: A Case Report and Review of the Literature

Paediatric Hepatitis B and Hepatitis C Virus Infections: An Observational Study of a Danish Cohort

Hepatitis-associated Aplastic Anaemia in Children

Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition

Hepatitis-associated Aplastic Anaemia in Children

Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the FISPGHAN

Viral hepatitis

Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.

Management of Hepatitis C Infection in children in the era of Direct-acting Antiviral Agents.

reatment and Monitoring of Children with Chronic Hepatitis C in the Pre-DAA Era: a European Survey of 38 Paediatric Specialists

Hepatitis C virus infection in children and adolescents

Glutathione peroxidase and malondialdehyde in children with chronic hepatitis C.

Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.

Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.

Advanced liver disease in Russian children and adolescents with chronic hepatitis C.

Hepatopathies in children and adolescents with type 1 diabetes

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection.

Epidemiology and natural history of hepatitis C virus infection among children and young people.

Hepatitis C virus infection in children: How do we prevent it and how do we treat it?

Hepatitis A, B, C and HIV seroprevalence among Syrian refugee children admitted to outpatient clinics.

Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper

Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection

Children Treated With Pegylated Interferon alfa-2a ± Ribavirin for Chronic Hepatitis C

Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies

Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution

Hepatitis C in Children Co-infected With Human Immunodeficiency Virus

Cognitive function and endogenous cytokine levels in children with chronic hepatitis C

Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C

EASL Recommendations on Treatment of Hepatitis C 2015

Labour productivity losses caused by premature death associated with hepatitis C in Spain.

Hepatic progenitor cells in children with chronic hepatitis C: correlation with histopathology, viremia, and treatment response

Dried blood spot in the genotyping,quantification and storage of HCV RNA: a systematic literature review.

Peginterferon-alfa mono-therapy in the treatment of acute hepatitis C in HIV-infection

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis

Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome

Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin

Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects

Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells

The rapid evolution of treatment strategies for hepatitis C

Maternal-fetal transmission of hepatitis C infection: what is so special about babies?

Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with Chronic Hepatitis C

Treatment of patients with dual hepatitis C virus and hepatitis Bvirus infection: Resolved and unresolved issues

Perinatal transmission of Hepatitis C virus

α-fetoprotein levels after interferon therapy and risk of hepato-carcinogenesis in chronic hepatitis C

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection-A Randomized Trial

Randomized controlled trial of Danoprevir plus peginterferonalfa-2a and Ribavirin in treatment-naïve patients with Hepatitis C virus genotype-1 infection

A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors

Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C

All-oral therapy with nucleotide inhibitors sofosbuvirand GS-0938 for 14 days in treatment - naive genotype 1 hepatitis C (nuclear)

Is 3 the new 1: Perspectives on Virology, Natural History and Treatment for Hepatitis C Genotype 3.

Up-regulation of circulating miR-20a is correlated with Hepatitis C virus-mediated liver disease progression

Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients

Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia

Dietary Fructose Intake and Severity of Liver Disease in Hepatitis C Virus-infected Patients

Plasma Interferon-gamma-Inducible Protein-10 (IP-10) Levels During Acute Hepatitis C Virus Infection

FAQ on Hepatitis C

What is hepatitis C?

Hepatitis C is the disease of the liver caused due to infection by hepatitis C virus (HCV). It is one of the common causes of chronic liver disease and may to progressive liver disease. It is also the leading indication for liver transplantation.

How common is hepatitis C infection?

It has been estimated that the globally around 2% are infected with HCV. 170 million people are chronically infected the virus. Also 3 to 4 million people get newly infected with the virus each year. In India around 1-2% of people are infected with this virus. The disease is common among children who require multiple transfusions like those suffering from Thalassemia and hemophilia.

Read more

CLF Intro movie

Financial Aid Offered by Trusts

Follow us on: